治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会

南方财经网08-13

8月13日，荣昌生物（688331.SH，09995.HK）公告，其自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普用于治疗全身型重症肌无力的Ⅲ期临床研究，达到方案设计的临床试验主要研究终点。临床研究结果显示，泰它西普可持续有效改善全身型重症肌无力患者的临床症状，显示良好的疗效和安全性。荣昌生物将择机向国家药品监督管理局药品审评中心（CDE）递交上市申请。南财快讯记者以投资者身份致电...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2459092091?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-13 17:54","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2459092091","market":"sh","top_or_hot":-1,"title":"治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会","media":"南方财经网","content":"<div>\n<p>8月13日，荣昌生物（688331.SH，09995.HK）公告，其自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普用于治疗全身型重症肌无力的Ⅲ期临床研究，达到方案设计的临床试验主要研究终点。临床研究结果显示，泰它西普可持续有效改善全身型重症肌无力患者的临床症状，显示良好的疗效和安全性。荣昌生物将择机向国家药品监督管理局药品审评中心（CDE）递交上市申请。南财快讯记者以投资者身份致电...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-13 17:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b><strong>南方财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月13日，荣昌生物（688331.SH，09995.HK）公告，其自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普用于治疗全身型重症肌无力的Ⅲ期临床研究，达到方案设计的临床试验主要研究终点。临床研究结果显示，泰它西普可持续有效改善全身型重症肌无力患者的临床症状，显示良好的疗效和安全性。荣昌生物将择机向国家药品监督管理局药品审评中心（CDE）递交上市申请。南财快讯记者以投资者身份致电...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b","article_id":"2459092091","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2459092091","pubTimestamp":1723542844,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"临床研究结果显示，泰它西普可持续有效改善全身型重症肌无力患者的临床症状，显示良好的疗效和安全性。7月24日，荣昌生物发布公告称，董事会对发行方案中的募集资金规模及相关事项进行调整，将拟募资额从不超25.5亿元调整至不超19.53亿元，投向新药研发项目。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","688331":"荣昌生物","09995":"荣昌生物","BK0239":"医药制造","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC"},"translate_title":"The phase III clinical effect of the innovative drug for the treatment of myasthenia gravis is good! Rongchang Biotech responded: Relevant briefings may be held after the interim report","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688331":1,"09995":0.9},"content_text":"8月13日，荣昌生物（688331.SH，09995.HK）公告，其自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普用于治疗全身型重症肌无力的Ⅲ期临床研究，达到方案设计的临床试验主要研究终点。临床研究结果显示，泰它西普可持续有效改善全身型重症肌无力患者的临床症状，显示良好的疗效和安全性。荣昌生物将择机向国家药品监督管理局药品审评中心（CDE）递交上市申请。南财快讯记者以投资者身份致电荣昌生物询问泰它西普商业化等相关事宜，相关人士表示，目前处于静默期，不方便答复。在中报发布后，可能会举行相关说明会。记者还注意到，荣昌生物在今年1月和7月均经历了股价大幅下跌。此外，该公司2024年第一季度亏损了3.49亿元。在这背后，市场对荣昌生物业绩和资金链的讨论不绝于耳。7月9日，荣昌生物举行电话会议，并在公告中披露了会议纪要，包括RC18国际合作进展、现金流情况以及海外专利到期等问题。针对市场高度关注的现金流问题，荣昌生物回应称公司在资金方面做了充分的准备：账上有一定的现金储备；商业化带来一定规模的现金流；拥有充足的银行授信；潜在的国际合作也有可能带来一定规模的现金流；资本市场融资。7月24日，荣昌生物发布公告称，董事会对发行方案中的募集资金规模及相关事项进行调整，将拟募资额从不超25.5亿元调整至不超19.53亿元，投向新药研发项目。截至8月13日收盘，荣昌生物A股跌0.96%，报26.90元/股，港股跌0.97%，报14.24港元/股。（声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。）文章来源：南方财经网原标题：治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459092091"}